Vés al contingut

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate theSafety, Efficacy, Pharmacodynamics, and Pharmacokinetics of SAR339375 forSubcutaneous Injection Administered Every Week in Patients with Alport Syndrome

  • Codi protocol: ACT16248
  • Codi EudraCT: 2016-002181-32
  • Grup de recerca: Nefrologia i Trasplantament Renal
  • Servei: Nefrologia
  • Investigador/a principal:  Soler Romeo, Maria Jose
  • Fase: Fase II
  • Status: Reclutant voluntaris